Monochemotherapy of bronchogenic carcinoma withs special reference to cell type.
D000230:Adenocarcinoma / Q000188:drug therapy; D000477:Alkylating Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D003561:Cytarabine / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005467:Floxuridine / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy; D008466:Mechlorethamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008937:Mitomycins / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D008926:Plicamycin / Q000627:therapeutic use; D011160:Porfiromycin / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D013308:Streptonigrin / Q000627:therapeutic use; D013852:Thiotepa / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D008937:Mitomycins; D009607:Nitrosourea Compounds; D005467:Floxuridine; D003561:Cytarabine; D003609:Dactinomycin; D013308:Streptonigrin; D011344:Procarbazine; D008466:Mechlorethamine; D014747:Vinblastine; D004317:Doxorubicin; D013852:Thiotepa; D011160:Porfiromycin; D008926:Plicamycin; D006918:Hydroxyurea; D008727:Methotrexate; D003630:Daunorubicin